CLOs on the Move

Faze Medicines

www.fazemed.com

 
Faze Medicines is a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.fazemed.com
  • 215 First Street Suite 440
    Cambridge, MA USA 02142
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Covance Labs

Covance Labs is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entegrion

Entegrion is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Polarity TE

PolarityTE, is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients` own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient`s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine.

IgGenix

IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake`s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau.

Lyell

We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for solid tumor cancers.